TransMedics Group Inc.
Rating
Updated: Aug 20, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stag...
Latest News
6 days ago · defenseworld.net
TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying ActivityTransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492
8 days ago · seekingalpha.com
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptTransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
8 days ago · gurufocus.com
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDXFormer Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
12 days ago · prnewswire.com
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial OutlookANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.
15 days ago · prnewswire.com
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
19 days ago · gurufocus.com
TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells InvestorsOn September 03, 2026, TransMedics Group Inc (TMDX) shares rose 3.2% to a current price of $86.98, which is situated within a 52-week range of $60.11 to $156.00
19 days ago · zacks.com
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
19 days ago · zacks.com
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
22 days ago · gurufocus.com
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDXRosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
22 days ago · prnewswire.com
TransMedics to Present at Upcoming September Investor ConferencesANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TMDX